AI SUMMARY

Research indicates that ivermectin may serve as a potential adjunct therapy for Parkinson’s disease by enhancing dopaminergic signaling, though it is not an FDA-approved treatment and requires further clinical validation.  Preclinical studies demonstrate that ivermectin increases dopamine release in the dorsal striatum primarily by activating cholinergic interneurons and modulating nicotinic acetylcholine receptors, potentially improving motor behaviors when combined with standard L-DOPA therapy.

Mechanistically, ivermectin acts as a positive allosteric modulator of P2X4 receptors and exhibits anti-neuroinflammatory properties, which may help mitigate microglial activation and alpha-synuclein aggregation associated with Parkinson’s pathology.  While a 2024 peer-reviewed study confirmed its ability to boost dopamine release independent of P2X4 pathways, these findings remain preclinical, with no completed human clinical trials to date.

Emerging anecdotal evidence from 2025 case reports, including those by Dr. William Makis, describes significant symptom improvement in patients using high-dose ivermectin (often combined with fenbendazole). However, these reports are uncontrolled and methodologically limited, and the safety of such high doses specifically for Parkinson’s patients has not been formally evaluated, necessitating cautious interpretation and urgent rigorous clinical trials.

What are the risks of high-dose ivermectin for Parkinson’s?

Researched high-dose ivermectin risks for Parkinson’s

The main risks of high-dose ivermectin (1–1.5 mg/kg/day, as used in the 2025 PD case reports) fall into several categories:

Neurotoxicity
Ivermectin normally stays out of the brain thanks to P-glycoprotein efflux pumps at the blood-brain barrier.  At high doses — or when P-gp is compromised by neuroinflammation or P-gp inhibitor drugs (e.g., amiodarone, ketoconazole, verapamil) — it enters the CNS and hyperactivates GABA-A receptors, causing confusion, visual blurriness, ataxia, deep sedation, and in severe cases respiratory depression.  In one documented PD case, a patient developed transient visual disturbances that resolved within 48 hours of stopping the protocol.

Symptom overlap with Parkinson’s
Neurological side effects like dizziness, tremor, and confusion can mimic or worsen PD symptoms, making it difficult to tell whether the drug is helping or harming.  This is a particular concern in an already neurologically vulnerable population.

Hepatotoxicity
High doses have been associated with transient aminotransferase elevations and rare cases of clinically apparent liver injury.  A pharmacovigilance study of 1,393 adverse event reports identified six serious hepatic events. The mechanism is unknown.

Drug interactions
PD patients typically take multiple medications (L-DOPA, MAO-B inhibitors, dopamine agonists, etc.). The interaction risk with P-gp inhibitors is the most critical, as it can convert a “safe” dose into a neurotoxic one.

Cell-level neurotoxicity
In vitro studies show ivermectin is toxic to human neurons (SH-SY5Y cells) via oxidative stress and mitochondrial pathway activation — the opposite of the neuroprotective effect being sought.

No established safety margin
The standard antiparasitic dose is 0.2–0.4 mg/kg (single dose). The doses in PD case reports are 5–7.5× that, taken daily and chronically.  No controlled trial has defined a safe upper limit for this population, and the 2002 study showing no CNS toxicity at 10× the standard dose used healthy young adults, not elderly PD patients on polypharmacy.

In short: the risk profile is dominated by dose-dependent CNS toxicity that is hard to distinguish from PD progression, compounded by drug interactions and the absence of any validated dosing protocol.  Any use outside a formal clinical trial should involve close medical supervision.